ScoreComparison
Why is Verrica Pharmaceuticals, Inc. ?
1
With a growth in Net Sales of 1380.23%, the company declared Outstanding results in Sep 25
- NET SALES(HY) Higher at USD 27.05 MM
- OPERATING PROFIT(Q) Highest at USD 1.81 MM
- PRE-TAX PROFIT(Q) Highest at USD -0.31 MM
2
Rising Promoter Confidence
- Promoters have increased their stake in the company by 2.5% over the previous quarter and currently hold 2.5% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Verrica Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Verrica Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Verrica Pharmaceuticals, Inc.
-11.51%
-0.06
852.72%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
99.79%
EBIT Growth (5y)
9.35%
EBIT to Interest (avg)
-10.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.63
Sales to Capital Employed (avg)
0.48
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
67.64%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-6.22
EV to EBIT
-7.59
EV to EBITDA
-8.02
EV to Capital Employed
-35.65
EV to Sales
3.88
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend29What is working for the Company
NET SALES(HY)
Higher at USD 27.05 MM
OPERATING PROFIT(Q)
Highest at USD 1.81 MM
PRE-TAX PROFIT(Q)
Highest at USD -0.31 MM
NET PROFIT(Q)
Highest at USD -0.31 MM
RAW MATERIAL COST(Y)
Fallen by -9,227% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 8.32 times
-1What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 36.49 MM
Here's what is working for Verrica Pharmaceuticals, Inc.
Net Sales
At USD 27.05 MM has Grown at 696.41%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Profit
Highest at USD 1.81 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -0.31 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -0.31 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Higher at USD 27.05 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Pre-Tax Profit
At USD -0.31 MM has Grown at 98.64%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -0.31 MM has Grown at 98.64%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 8.32 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -9,227% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Verrica Pharmaceuticals, Inc.
Cash and Eqv
Lowest at USD 36.49 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
